RUNX3 and neoplasm: Additional evidence for this interaction stems from colorectal cancer studies where upregulation of RUNX3 by Bone Morphogenetic Protein (BMP) reduces c-MYC expression, thereby exerting c-MYC tumour-suppressor activity (Lee et al., 2010).